EAACI Congress 2024
BackOAS 10 - Advances in Chronic Urticaria treatment
Saturday 01 Jun, 08:30 AM -
10:00 AM Valencia, Spain
Granada
Oral Abstract Sessions
08:30
Effect of Remibrutinib on Disease Activity in Patients with Chronic Spontaneous Urticaria: Post Hoc Analysis of Phase 3 REMIX-1 and REMIX-2 studies
08:42
Rilzabrutinib Results in Rapid Improvement of Symptoms in Patients With Chronic Spontaneous Urticaria: Results From the RILECSU Phase 2 Dose-Ranging Study
08:54
Minimal persistent inflammation in chronic spontaneous urticaria patients with clinical remission
09:06
Effect of Remibrutinib on Sleep and Daily Activities in Patients With Chronic Spontaneous Urticaria: Results From the Phase 3 Studies
09:18
Rilzabrutinib Reduces IgG Anti-Thyroid Peroxidase (anti-TPO), Soluble Mas-Related G Protein-Coupled Receptor X2 (sMRGPRX2) and Eosinophils at 12 Weeks in Patients With Chronic Spontaneous Urticaria
09:30
Chronic urticaria across the ages: clinical features, comorbidities, and treatment response
09:42
The BEACON Study: A Phase 1b/2a, Dose Escalation Study of Safety, Pharmacokinetic/Pharmacodynamic and Preliminary Clinical Activity of the c-Kit Mab Briquilimab in Adults with symptomatic Chronic Spontaneous Urticaria (CSU)